NovImmune SA Stock

Novimmune SA is a Switzerland-based drug discovery and development company. The Company develops therapeutic agents for the targeted treatment of immune-related disorders, inflammatory diseases and cancer. The Company's product portfolio encompasses approximately ten monoclonal antibodies. The pipeline is a balance of preclinical and clinical compounds, specific for clinically validated and new targets. The Company's six compounds are in early clinical development with the three in clinical Phase II. In addition to these compounds, the Company develops around two antibody generation platforms, a monoclonal antibody platform and a bispecific antibody platform, designed to streamline the identification, production and characterization of fully-human antibodies.